May 2, 2016
Oncternal Therapeutics, a new cancer-focused biotechnology startup, has signed a wide-ranging licensing agreement with UC San Diego to develop and commercialize antibodies and antibody-related binding agents.
March 25, 2013
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.
September 16, 2014
Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.
May 6, 2022
UC San Diego researchers describe the underlying signaling pathway that results in pulmonary arterial hypertension and a novel monoclonal antibody therapy that blocks the abnormal blood vessel formation characterizing the disease.
August 5, 2020
The National Institutes of Health will soon launch a Phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.
April 7, 2014
The difference between an immune response that kills cancer cells and one that conversely stimulates tumor growth can be as narrow as a “double-edged sword,” report researchers at the University of California, San Diego School of Medicine in the April 7, 2014 online issue of the Proceedings of the National…
November 19, 2024
The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a monoclonal antibody, and durvalumab, an immune checkpoint inhibitor.
July 3, 2012
Research suggests that patients with leukemia sometimes relapse because standard chemotherapy fails to kill the self-renewing leukemia initiating cells, often referred to as cancer stem cells. In such cancers, the cells lie dormant for a time, only to later begin cloning, resulting in a return and metastasis of the disease.…
March 1, 2021
A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo.
December 21, 2015
Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the…
